Skip to main content
SpringerLink
Log in

Troxacitabine

BCH 4556, SPD 758, Troxatyl

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

Troxacitabine [BCH 4556; SPD 758; Troxatyl] is a DNA synthesis inhibitor.1 It is a member of a novel class of nucleoside analogues discovered by BioChem Pharma and is the first example of a synthetic L-nucleoside analogue to have shown anticancer activity in animal models. On 11 May 2001, BioChem Pharma was acquired by, and integrated into, Shire Pharmaceuticals Group.

In February 2002 Shire announced that it intended to pursue development of troxacitabine as a treatment for solid tumours. In addition, Shire indicated that it would pursue the drug’s development for acute myeloid leukaemia.

In March 1999, phase II trials were initiated to investigate the efficacy and tolerability of troxacitabine in a variety of solid tumours including pancreas, prostate, colorectal, renal and non-small cell lung cancers and melanoma. The trials were conducted throughout North America and were closed to patient accrual in 2000.

Two phase I combination chemotherapy trials in solid tumours (one with cisplatin and another with paclitaxel) have been initiated. One of these trials is in patients with pancreatic cancer. A phase III trial in patients with pancreatic cancer is expected to begin during the second or third quarter of 2003.

In addition, further clinical development was initiated in May 2000, in the form of a combination chemotherapy trial in patients with acute leukaemia.

A phase II trial in patients with acute myeloid leukaemia (AML) and chronic myeloid leukaemia-blast phase (CML-BP) has reported that troxacitabine demonstrated significant activity in these cancers. However, Shire indicated that no further development for CML-BP will be conducted. The company indicated that it would focus future development in the haematological malignancy area on AML and has initiated an exploratory phase III trial of troxacitabine in previously untreated patients with poor prognosis AML. The study will compare troxacitabine in combination with either cytarabine or idarubicin, with a control drug regimen. The aim is to identify the most promising treatment regimens in a relatively small number of patients before commencing the larger pivotal trial. A pivotal phase III trial is expected to begin in the first half of 2003.

In September 2002, Shire Pharmaceuticals forecast Troxatyl™ to reach peak sales of $US100–200 million, for the indications of pancreatic cancer and myeloid leukaemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Stephenson Jr J, Baker SD, Aylesworth C. A phase I safety and pharmacokinetic study of BCH-4556, a novel L-nucleoside antimetabolite, on a daily x 5 day every 21-day schedule in patients with solid neoplasms. Annals of Oncology 9 (Suppl. 2): 156, 1998

    Google Scholar 

  2. Bélanger K, Moore M, Siu L. A phase I study of the L-nucleoside analogue B-L-dioxolane-cytidine (BCH-4556) given as a 30 minute infusion every 21 days. 35th Annual Meeting of the American Society of Clinical Oncology 18: 197, 15 May 1999

    Google Scholar 

  3. Canova A, Yee L, Baker S. A phase I and pharmacokinetic study of beta-L-dioxalo-cytidine (BCH-4556) administered weekly for three weeks every 28 days. 35th Annual Meeting of the American Society of Clinical Oncology 18: 197, 15 May 1999

    Google Scholar 

  4. Baker SD, Stephenson J, Goetz A. Determinants affecting beta- L-dioxolane-cytidine (BCH-4556) exposure and relationship with toxicity in phase I trials. 35th Annual Meeting of the American Society of Clinical Oncology 18: 197, 15 May 1999

    Google Scholar 

  5. Stephenson J, Baker SD, Simmons C, et al. Phase I and pharmacokinetic study of troxacitabine (b-L-dioxolan-cytidine; BCH-4556) on a daily × 5 day every 4-week schedule. European Journal of Cancer 35 (Suppl. 4): 284, Sep 1999

    Article  Google Scholar 

  6. Moore M, Belanger K, Jolivet J, et al. NCIC CTG IND 103: a phase I and pharmacokinetic study of the novel L-nucleoside analog troxacitabine (BCH-4556) given every 21 days. European Journal of Cancer 35 (Suppl. 4): 284, Sep 1999

    Article  Google Scholar 

  7. Moore M, Belanger K, Dionne J, et al. Troxacitabine (BCH-4556), a nucleoside analog with distinct stereochemical, pharmacologic and pharmacokinetic characteristics is tolerable and active in phase I studies: the NIC-C CTG experience. Clinical Cancer Research 5 (Suppl.): 3729, Nov 1999

    Google Scholar 

  8. BioChem Pharma Inc. BioChem Pharma Inc — new studies to evaluate troxatyl (TM) in leukemia patients. Media Release: [4 pages], 4 Dec 2000. Available from: URL: rs http://www.bi-ochem-pharma.com url

  9. Giles F, Belanger R, Toor A, et al. A phase I/II multi-center study of Troxatyl TM in patients with refractory chronic lymphocytic leukemia, lymphoma or multiple myeloma. Blood 98: 289, Part 2, 16 Nov 2001

    Google Scholar 

  10. Kadhim S, Waud W, Angers E. BCH-4556: a novel nucleoside analog with potent in vivo activity against renal cancer. 88th Annual Meeting of the American Association for Cancer Research: 99–100, 12 Apr 1997

    Google Scholar 

  11. Bowlin T, Genne P, Kadhim S. A novel cytidine nucleoside analogue, BCH-4556, with potent activity against human anthracycline-resistant leukaemia. 88th Annual Meeting of the American Association for Cancer Research: 100, 12 Apr 1997

    Google Scholar 

  12. Rabbani SA, Harakidas P, Bowlin T. Prevention of prostate cancer progression and metastasis by a novel nucleoside analogue. 88th Annual Meeting of the American Association for Cancer Research: 100, 12 Apr 1997

    Google Scholar 

  13. Attardo G, Kadhim S, Angers E. Dose scheduling effects on the antitumor activity of BCH-4556 against human tumor xenografts in nude mice. 88th Annual Meeting of the American Association for Cancer Research: 100, 12 Apr 1997

    Google Scholar 

  14. Roeltgen D, Ross J. Role of estrogen deficiency in cognitive function of women and premature ovarian failure. Neurology 56 (Suppl. 3): 52, 2001

    Google Scholar 

  15. Kadhim SA, Bowlin TL, Waud WR, et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Research 57: 4803–4810, 1 Nov 1997

    PubMed  CAS  Google Scholar 

  16. Rabbani SA, Harakidas P, Bowlin T, et al. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Research 58: 3461–3465, 1 Aug 1998

    PubMed  CAS  Google Scholar 

  17. Giles FJ, Garcia-Manero G, Cortes JE, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. Journal of Clinical Oncology 20: 656–664, 1 Feb 2002

    Article  PubMed  CAS  Google Scholar 

  18. Dent SF, Arnold A, Stewart D, et al. NCIC CTG IND 120: phase II study of troxacitabine in patients with advanced non-small cell lung cancer. 37th Annual Meeting of the American Society of Clinical Oncology 20: 259, Part 2, 12 May 2001

    Google Scholar 

Download references

Author information

Consortia

Adis Editorial

Additional information

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adis Editorial. Troxacitabine. Drugs R&D 4, 264–268 (2003). https://doi.org/10.2165/00126839-200304040-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304040-00010

Keywords

Search

Navigation